Navigation Links
Bradmer provides clinical trial update and announces evaluation of strategic alternatives
Date:2/17/2009

TSX: BMR

TORONTO, Feb. 17 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc. (BMR.TSX), provided an update today on the ongoing Phase III GLASS-ART Trial testing Neuradiab(R) in the most advanced form of brain cancer (glioblastoma). Bradmer also announced that its Board of Directors has recommended a review of strategic options in light of performance, market conditions and new projections of site initiation and patient enrollment from the Company's clinical research organization (CRO).

During the second half of 2008, the Phase III GLASS-ART Trial was successfully launched with five clinical trial sites activated and another 15 sites near initiation with regulatory and budgeting processes completed. Bradmer has now also completed a review of the first cohort of patients.

"We have enrolled our first cohort of patients in the trial and documented the appropriateness of dosing and protocol compliance with no reports of any serious adverse events," said Dr. Alan M. Ezrin, President and Chief Executive Officer. "While the efficiency and quality review of the Phase III study to date yielded encouraging protocol adherence and proof of execution, it also revealed significant logistical issues."

The Company's present CRO has indicated that it is unable to meet the targets for site initiation and enrollment of sufficient patients in a timely manner. This has occurred despite Bradmer having secured participation of multiple key centers across the United States. This projected delay in patient enrollment translates into a longer time to reach key clinical milestones that would require additional capital beyond 2009 to complete a planned 60-patient "run-in phase" and full trial enrollment.

The Company has terminated the relationship with the CRO which has agreed to continue through any "transition" or "wind down" phase. Management and the Board of Directors of Bradmer are now examining the ramification of this delay and
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Bradmer to participate in panel presentation at RBC Capital Markets Healthcare Conference
2. Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting
3. Bradmer announces 2008 third quarter operational and financial results
4. Bradmer to present at Rodman & Renshaw Healthcare Conference
5. Bradmer receives FDA approval to proceed with Phase III clinical trial
6. Bradmer announces 2008 first quarter operational and financial results
7. Bradmer announces new additions to management team
8. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
9. Notice of Bradmer Pharmaceuticals Conference Call
10. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
11. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2014)... lung cancer are 70 years of age or older, ... not well represented in clinical trials. Therefore, the paucity ... evidence based clinical recommendations. , In 2010, the EORTC ... Group along with the International Society for Geriatric Oncology ... elderly patients with non-small cell lung cancer (NSCLC), and ...
(Date:4/22/2014)... to trauma, illness, alcohol or other drug abuse, these ... cells that can go awry and activate conditions such ... autism. , Until now, it has been unclear how ... developing brain. Past studies have shown that when an ... or she experiences some trauma or illness, her baby ...
(Date:4/22/2014)... (April 22, 2014) Cedars-Sinai stroke intervention researchers have ... and Stroke, part of the National Institutes of Health, ... multicenter Phase II clinical trial of an experimental drug ... used in combination with recombinant tissue plasminogen activator, or ... ischemic strokes shortly after onset. In laboratory rodent studies, ...
(Date:4/22/2014)... Based on results of a clinical trial ... Food and Drug Administration (FDA) approved a molecularly ... cancer that has progressed after standard chemotherapy has ... review was announced by the manufacturer, Lilly Oncology, ... name ramucirumab, it will be sold under the ...
(Date:4/22/2014)... of the University of Calgary,s Hotchkiss Brain Institute (HBI) ... cells as a means to restore connections after injury. ... key molecule that directly regulates nerve cell growth in ... the prestigious journal Nature Communications , with lead ... "We made the surprising discovery that a protein called ...
Breaking Medicine News(10 mins):Health News:EORTC and SIOG update expert opinion on management of elderly patients with NSCLC 2Health News:Life stressors trigger neurological disorders, researchers find 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3Health News:FDA approves first targeted drug for advanced stomach cancer 2Health News:Scientists discover a new way to enhance nerve growth following injury 2
... BELLEVUE, Wash. and WASHINGTON, Oct. 4 Revolution,Health ... fastest growing health,properties, and drugstore.com (Nasdaq: DSCM ... and pharmacy products, today announced a major,agreement whereby ... the Revolution Health Network and manage advertising sales ...
... and Research,s (A*STAR) Institute of Molecular and Cell ... provide a more detailed understanding of how the ... albicans transforms into a serious and often life-threatening ... serious and potentially life-threatening infections in the mouth, ...
... FAIRFAX, Va., Oct. 4 SRA International, Inc.,(NYSE: ... and strategic consulting,services and solutions to federal government ... an enterprise-wide infrastructure,architecture for the Department of Justice ... Support Services-3 contract, has an,estimated value of $59 ...
... ,Tour to Insure, will Highlight Need to Reduce,Costs, Expand ... G.,Rendell will continue his campaign to reduce the costs ... with the passage of the,remainder of his "Prescription for ... bus tour. The five-day, nine-stop "Tour to Insure",will include ...
... operational,clinical and technological innovator in emergency medical services, ... ground, this time in the,way it hires the ... and around,Charlotte, N.C. While the nation,s emergency ... already trained in an academic setting,Medic is hiring ...
... Drive for Decision, CHARLESTON, S.C., Oct. 4 ... to introduce a proactive self-funding process to,secure the ... for the domestic shrimping industry. Beginning in January ... combination of federal government,assistance, voluntary industry contributions, foundation ...
Cached Medicine News:Health News:drugstore.com and Revolution Health Group Announce Breakthrough Deal 2Health News:drugstore.com and Revolution Health Group Announce Breakthrough Deal 3Health News:How Candida albicans transforms from its normally benign form into life-threatening form 2Health News:Department of Justice Awards $59M Task Order to SRA 2Health News:Governor Rendell to Fight to 'Cover All Pennsylvanians' During Statewide Bus Tour 2Health News:Mecklenburg EMS Agency Launches Innovative Program to Pay Future EMT's While They Train 2Health News:Wild American Shrimp Board Agrees To Implement New Self-Funding Measures 2
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... it expects revenues for the fourth quarter of 2013 ... revenues to approximately $208 million. "Our full-year ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led by ... a premier and affordable laser tattoo removal experience with the ... focus is in providing high quality cosmetic services with cutting edge ... " Southern California has seen a dramatic ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... Connecticut waterways may be safer from biomedical waste, thanks ... program. CEDF, with loan-program partners, Connecticut ,s Department of Economic and Community ... loan to a West Haven company that stems improper disposal of ... , West ...
... 14 Hospira, Inc. (NYSE: ... medication delivery company, will expand its commitment to non-DEHP ... of non-DEHP intravenous (I.V.) administration sets. This effort reflects ... and reduced impact on the environment, and coincides with ...
Cached Medicine Technology:West Haven Firm Expands Biomedical Disposal Program with Community Economic Development Fund 2Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP 2Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP 3Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP 4
Full Handle Laseredge Stab Blade Knife, 30 blade. Blade tip dimension: 10.5 mm x 1.9 mm x 3.4 mm....
19 Gauge. Reusable. Block of 4 each....
Set consist of two 27 gauge, stainless steel probes with blunt tips. Probes are 11.5 cm (4.5 inches) long with 30.5 cm (12 inches) of flexible tubing (O.D. - 0.60 mm, I.D. - 0.30 mm) attached onto th...
19 gauge x 8 mm with 15 cm high pressure extension tube preattached to a 10C ring control syringe. 3 per box....
Medicine Products: